Publicaciones en colaboración con investigadores/as de Imperial College London (24)

2024

  1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx (Nature, (2023), 616, 7957, (525-533), 10.1038/s41586-023-05783-5)

    Nature

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  3. HRD testing for all advanced high-grade ovarian carcinoma in first line?

    ESMO Open

  4. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics, Vol. 56, Núm. 10, pp. 2121-2131

  5. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

  6. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

  7. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer, Vol. 5, Núm. 2, pp. 347-363

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 833-845

  4. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  5. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  6. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308

  7. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533

  8. The evolution of non-small cell lung cancer metastases in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 534-542

  9. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Nature, Vol. 616, Núm. 7957, pp. 553-562

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

2021

  1. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190

  2. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    Radiotherapy and Oncology, Vol. 154, pp. 327-353

  3. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39